To critically evaluate the published literature assessing the safety and efficacy of thrombolytic therapy for massive and submassive pulmonary embolism (PE).
Methods:
A search of human trials in the English-language (September 2017) was conducted through the MEDLINE database using the following terms: PE, tissue plasminogen activator, tenecteplase, and alteplase. 67 unique articles were identified, of which 24 clinical trials discussing clinical outcomes related to administration of either intravenous tenecteplase or alteplase were included.
Results:
Thrombolytic therapy with anticoagulation significantly reduced mortality compared to anticoagulation alone in massive PE. In submassive PE, thrombolytics reduced the rate of right ventricular dysfunction and hemodynamic collapse; however, there is an increased risk of major and minor bleeding with no benefit on long-term functional outcomes.
Conclusions:
Patients with massive PE should receive thrombolytics when no major contraindications to therapy exist. Patients with submassive PE at highest risk for progression to hemodynamic instability should receive anticoagulation and be monitored for clinical deterioration. If an imminent risk of hemodynamic instability or cardiac arrest occurs, thrombolytics should be administered if no contraindications exist. Net mortality benefit and risk of bleeding must be considered when deciding to administer thrombolytic therapy in massive or submassive PE.
HorlanderKTManninoDMLeeperKV. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med. 2003;163(14):1711–1717.
2.
KonstantinidesSVTorbickiAAgnelliG, et al.For the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC).2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(43):3033–3069.
3.
JaffMRMcMurtyMSArcherSL, et al.Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American heart association. Circulation. 2011;123(16):1788–1830.
4.
JimenezDKopecnaDTapsonV, et al.Derivation and validation of multimarker prognostication for normotensive patients with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med. 2014;189(6):718–726.
5.
KearonCAklEAComerotaAJ, et al.For the American college of chest physicians. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(suppl 2):e419S–e4196S.
6.
KearonCAklEAOrnelasJ, et al.Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352.
7.
BecattiniCCohenATAgnelliG, et al.Risk stratification of patients with acute symptomatic pulmonary embolism based on presence or absence of lower extremity DVT: systematic review and meta-analysis. Chest. 2016;149(1):192–200.
8.
VanniSVivianiGBaioniM, et al.Prognostic value of plasma lactate levels among patients with acute pulmonary embolism: the thrombo-embolism lactate outcome study. Ann Emerg Med. 2013;61(3):330–338.
9.
VanniSJiménezDNazerianP, et al.Short-term clinical outcome of normotensive patients with acute PE and high plasma lactate. Thorax. 2015;70(4):333–338.
10.
HariharahanPDudzinskiDMRosovskyR, et al.Relation among clot burden, right-sided heart strain, and adverse events after acute pulmonary embolism. Am J Cardiol. 2016;118(10):1568–1573.
11.
Activase (alteplase) [package insert]. South San Francisco, CA: Genentech, Inc.; 2015.
12.
FenglerBTBradyWJ. Fibrinolytic therapy in pulmonary embolism: an evidence-based treatment algorithm. Am J Emerg Med. 2009;27(1):84–95.
13.
JauchECSaverJLAdamsHPJr, et al.Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke. 2013;44(3):870–947.
14.
TNKase (tenecteplase) [package insert]. South San Francisco, CA: Genentech, Inc.; 2011.
15.
MeyerGVicautEDanaysT, et al.For the PEITHO investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370(15):1402–1411.
16.
Jerjes-SanchezCRamírez-RiveraAde Lourdes GarcíaM, et al.Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis. 1995;2(3):227–229.
17.
PollackCVSchreiberDGoldhaberSZ, et al.Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (multicenter emergency medicine pulmonary embolism in the real world registry). J Am Coll Cardiol. 2011;57(6):700–706.
18.
LaporteSMismettiPDecoususH, et al.For the RIETE investigators. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the registro informatizado de la enfermedad TromboEmbolica venosa (RIETE) registry. Circulation. 2008;117(13):1711–1716.
19.
GoldhaberSZVisaniLDe RosaM. Acute pulmonary embolism: clinical outcomes in the international cooperative pulmonary embolism registry (ICOPER). Lancet. 1999;353(9162):1386–1389.
20.
CaldicottDParasivamSHardingJ, et al.Tenecteplase for massive pulmonary embolus. Resuscitation. 2002;55:211–213.
21.
ShuklaANThakkarBJayaramAA, et al.Efficacy and safety of tenecteplase in pulmonary embolism. J Thromb Thrombolysis. 2014;38(1):24–29.
22.
WanSQuinlanDJAgnelliG, et al.Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation. 2004;110(6):744–749.
23.
SteinPDMattaF. Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. Am J Med. 2012;125(5):465–470.
24.
WangCZhaiZYangY, et al.For the China Venous Thromboembolism (VTE) study group. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest. 2010;137(2):254–262.
25.
GoldhaberSZAgnelliGLevineMN. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The bolus alteplase pulmonary embolism group. Chest. 1994;106(3):718–724.
26.
SorsHPacouretGAzarianR, et al.Hemodynamic effects of bolus 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest. 1994;106(3):712–717.
27.
Dalla-VoltaSPallaASantolicandroA, et al.PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol. 1992;20(3):520–526.
28.
GoldhaberSZHaireWDFeldsteinML, et al.Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993;341(8844):507–511.
29.
LevineMHirshJWeitzJ, et al.A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest. 1990;98(6):1473–1479.
30.
KonstantinidesSGeibelAHeuselG, et al.For the Management Strategies and Prognosis of Pulmonary Embolism-3 investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002;347(15):1143–1150.
31.
FasulloSScalzoSMaringhiniG, et al.Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin. Am J Med Sci. 2011;341(1):33–39.
32.
SharifiMBayCSkrockiL, et al.For the MOPETT investigators. Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” trial). Am J Cardiol. 2013;111(2):273–277.
33.
PIOPED Investigation Committee. Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED investigators. Chest. 1990;97(3):528–533.
34.
GoldhaberSZKesslerCMHeitJ, et al.Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet. 1988;332(8606):293–298.
35.
GoldhaberSZKesslerCMHeitJA, et al.Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol. 1992;20(1):24–30.
36.
MeyerGSorsHCharbonnierB, et al.Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. J Am Coll Cardiol. 1992;19(2):239–245.
37.
MeneveauNSchieleFVuillemenotA, et al.Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. Eur Heart J. 1997;18(7):1141–1148.
38.
MeneveauNSchieleFMetzD, et al.Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up 1. J Am Coll Cardiol. 1998;31(5):1057–1063.
39.
TebbeUGrafAKamkeW, et al.Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J. 1999;138(1 Pt 1):39–44.
40.
TebbeUBramlagePGrafA, et al.Desmoteplase in acute massive pulmonary thromboembolism. Thromb Haemost. 2009;101(3):557–562.
41.
BecattiniCAgnelliGSalviA, et al.For the TIPES study group. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res. 2010(3);125:e82–e86.
42.
KlineJANordenholzKECourtneyDM, et al.Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost. 2014;12(4):459–468.
43.
PengoVLensingAWPrinsMH, et al.For the thromboembolic pulmonary hypertension study group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350(22):2257–2264.
44.
GrifoniSOlivottoICecchiniP, et al.Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation. 2000;101(24):2817–2822.
45.
KlineJAHernandezJHoggMM, et al.Rationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes. Emerg Med Australas. 2013;25(6):515–526.
46.
StewartLKPeitzGWNordenholzKE, et al.Contribution of fibrinolysis to the physical component of the SF-36 after acute submassive pulmonary embolism. J Thromb Thrombolysis. 2015;40(2):161–166.
47.
KonstantinidesSVVicautEDanaysT, et al.Impact of thrombolytic therapy onthelong-term outcome of intermediate-risk pulmonaryembolism. J Am Coll Cardiol. 2017;69(12):1536–1544.
48.
ProviasTDudzinskiDMRosenfieldK, et al.The Massachusetts General Hospital Pulmonary Embolism Response Team (MGH PERT): creation of a multidisciplinary program to improve care of patients with massive and submassive pulmonary embolism. Hosp Pract (1995). 2014;42(1):31–37.
49.
CarrollBJPembertonHBauerKA, et al.Initiation of a multidisciplinary, rapid response team to massive and submassive pulmonary embolism. Am J Cardiol. 2017;120(8):1393–1398.
50.
SerhalMHaddadinISHeresiGA, et al.Pulmonary embolism response teams. J Thromb Thrombolysis. 2017;44(1):19–29.
